← All organizations
Highest phase reached
Phase 2
First clinical trial
Nov 1, 2005Last known activity
Feb 1, 2011
Defunct as of Jan 1, 2019
Timeline
2000s
- Jun 1, 2003
Ascenta Therapeutics— Founded
2010s
- Jan 1, 2019
Ascenta Therapeutics— Defunct
Drugs by trial phase (10 distinct, 12 trials)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Neoplasms
- Prostatic Neoplasms
- Small Cell Lung Carcinoma
Recent trials (21)
- NCT01265199Study directorPhase 1Feb 1, 2011
- NCT01265199Lead sponsorPhase 1Feb 1, 2011
- NCT00934076CollaboratorPhase 1Feb 1, 2010
- NCT00988169CollaboratorPhase 2Sep 1, 2009
- NCT00571675Study directorPhase 2Oct 1, 2007
- NCT00571675Lead sponsorPhase 2Oct 1, 2007
- NCT00544960Study chairPhase 2Sep 1, 2007
- NCT00544960Lead sponsorPhase 2Sep 1, 2007
- NCT00561197Study directorPhase 1/Phase 2Aug 1, 2007
- NCT00561197Lead sponsorPhase 1/Phase 2Aug 1, 2007
- NCT00397293Study chairPhase 1/Phase 2Nov 1, 2006
- NCT00397293Lead sponsorPhase 1/Phase 2Nov 1, 2006
- NCT00440388Study directorPhase 2Oct 1, 2006
- NCT00440388Lead sponsorPhase 2Oct 1, 2006
- NCT00286793Lead sponsorPhase 1/Phase 2Feb 1, 2006
Details
- Founded
- Malvern, PA, US Jun 1, 2003
- Last known activity
- Feb 1, 2011
Notes
Defunct but unclear when.